Peptides and combination of peptides for use in immunotherapy against various cancers
US-10314897-B2 · Jun 11, 2019 · US
Engineered Terminal Deoxynucleotidyl Transferase Variants
US2024182876A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2024182876-A1 |
| Application number | US-202318485855-A |
| Country | US |
| Kind code | A1 |
| Filing date | Oct 12, 2023 |
| Priority date | Oct 13, 2022 |
| Publication date | Jun 6, 2024 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides engineered terminal deoxynucleotidyl transferase (TdT) polypeptides useful in template-independent polynucleotide synthesis, as well as compositions, methods of utilizing these engineered polypeptides, and polynucleotides encoding the engineered terminal deoxynucleotidyl transferases.
First claim
Opening claim text (preview).
What is claimed is: 1 . An engineered terminal deoxynucleotidyl transferase comprising a polypeptide sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to a reference sequence selected from SEQ ID NO: 2, 8, 12, 16, 24, 36, 54, 268, 648, 660, 882, 1100, 1336, 1348, 1596, 1654, 1830, 1950, 2008, 2254, 2514, 2524, 2638, 2804, 2812, 2956, 3174, 3222, 3670, 3674, 3796, 3870, 3918, 4266, 4442, 4654, 4850, 4856, 4904, 5002, 5028, 5192, 5246, or a functional fragment thereof, and at least one amino acid residue difference relative to the reference sequence. 2 . The engineered terminal deoxynucleotidyl transferase of claim 1 , wherein the polypeptide sequence comprises residue differences relative to the reference sequence of SEQ ID NO: 2 at a set of amino acid positions selected from: 80/121/185/315; 80/121/185/190/289/290/293/313/342/499; 80/121/185/190/289/290/293/313/315/336/342/359/391/414/470/474/499/522/523; 80/121/185/190/244/289/290/293/313/315/317/336/342/359/391/470/474/499/522/523; 80/121/174/185/190/196/244/266/273/284/288/289/290/293/313/315/317/324/336/342/352/359/391/394/3 97/401/419/428/431/462/470/474/499/522/523; 80/106/121/185/190/205/289/290/293/313/315/336/342/359/391/470/474/499/522/523; 80/106/121/185/190/205/289/290/293/313/342/470/474/499/523; 80/106/121/185/190/244/289/290/293/307/342/359/470/474/499; 80/121/131/185/190/205/244/289/290/293/313/315/336/342/359/391/414/470/474/499/522/523; 80/121/131/185/190/205/244/289/290/293/313/336/342/359/391/414/470/474/499/522/523; 80/121/131/185/190/289/290/293/313/342/470/474/499/522/523; 80/121/174/179/185/190/236/244/288/289/290/293/313/315/317/336/342/359/363/391/394/408/426/462/4 70/474/499/522/523; 80/121/174/185/186/190/236/244/273/284/288/289/290/293/313/315/317/336/342/352/359/391/394/395/4 19/428/431/462/470/474/499/522/523; 80/121/174/185/190/193/196/244/273/284/288/289/290/293/297/313/315/317/324/336/342/352/359/376/3 80/391/394/401/415/419/428/431/435/441/462/470/474/499/522/523; 80/121/174/185/190/193/244/273/284/288/289/290/293/297/313/315/317/336/342/352/359/391/394/415/4 19/428/431/462/470/474/499/522/523; 80/121/174/185/190/236/244/273/282/284/288/289/290/293/313/315/317/336/342/352/359/391/394/395/4 19/428/431/462/470/474/499/522/523; 80/121/174/185/190/244/273/284/288/289/290/293/313/315/317/336/342/352/359/391/394/419/428/431/4 62/470/474/499/522/523; 80/121/174/185/190/244/273/284/288/289/290/293/313/315/317/336/342/359/391/394/428/431/462/470/4 74/499/522/523; 80/121/174/185/190/244/284/288/289/290/293/313/315/317/336/342/352/359/391/394/419/428/431/462/4 70/474/499/522/523; 80/121/174/185/190/244/284/288/289/290/293/313/315/317/336/342/352/359/391/394/428/431/462/470/4 74/499/522/523; 80/121/174/185/190/244/284/288/289/290/293/313/315/317/336/342/359/391/394/428/431/462/470/474/4 99/522/523; 80/121/185/190/196/244/289/290/293/313/315/317/336/342/359/391/470/474/499/522/523; 80/121/185/190/201/289/290/293/313/342/470/474/499/522; 80/121/185/190/244/273/289/290/293/313/315/317/336/342/352/359/391/419/435/470/474/499/522/523; 80/121/185/190/244/289/290/293/300/313/315/317/336/342/359/391/470/474/499/522/523; 80/121/185/190/244/289/290/293/313/315/317/336/342/359/380/391/401/419/470/474/499/522/523; 80/121/185/190/244/289/290/293/313/315/317/336/342/359/391/392/470/474/499/522/523; 80/121/185/190/244/289/290/293/313/315/317/336/342/359/391/395/470/474/499/522/523; 80/121/185/190/244/289/290/293/313/336/342/359/391/414/470/474/499/522/523; 80/121/185/190/289/290/293/313/336/342/359/391/470/474/499/522/523; 80/121/190/289/290; 80/185/236/289/293; 121/185/190/213/289/290/293; and 185/289/290/293. 3 . The engineered terminal deoxynucleotidyl transferase of claim 1 , wherein the polypeptide sequence comprises at least one substitution set comprising substitutions as compared to the reference sequence of SEQ ID NO: 36 at amino acid positions selected from: 174/244/273/284/288/315/317/336/352/359/391/394/419/428/431/462/470/474/522/523; 174/244/284/288/315/317/336/359/391/394/428/431/462/470/474/522/523; 244/315/317/336/359/391/470/474/522/523; and 336/359/391/470/474/522/523; and/or any combination thereof. 4 . The engineered terminal deoxynucleotidyl transferase of claim 1 , wherein the polypeptide sequence comprises at least one substitution or substitution set comprising substitutions as compared to the reference sequence of SEQ ID NO: 8 at amino acid positions selected from: 129/196, 173, 183, 186, 193, 195, 196, 263, 266, 268, 281, 282, 297, 300, 303, 316, 318, 320, 324, 343, 360, 392, 395, 397, 411, 415, 417, 421, 454, 456, 477, 481, and 492, and/or any combinations thereof. 5 . The engineered terminal deoxynucleotidyl transferase of claim 1 , wherein the polypeptide sequence comprises at least one substitution or substitution set comprising substitutions as compared to the reference sequence of SEQ ID NO: 16 at amino acid positions selected from: 186, 186/236/318, 186/236/395, 186/282/318, 193/196, 193/196/266/324/376/380, 193/196/297, 193/196/297/324/376/380/401/415/435/441, 193/196/324, 193/196/324/397/401/441, 193/196/376/380, 193/297/324/376/435, 193/297/324/380, 193/297/415, 193/435, 196, 196/266, 196/266/324/397/401, 196/297/324/435, 236/282, 236/282/395, 236/318/481, 266/297/380/397/401, 282, 282/318, 282/481, 297/380/401/441, 297/435, 318/395, 376/401/441, 415, and 435/441, and/or any combinations thereof. 6 . The engineered terminal deoxynucleotidyl transferase of claim 1 , wherein the polypeptide sequence comprises at least one substitution or substitution set comprising substitutions as compared to the reference sequence of SEQ ID NO: 24 at amino acid positions selected from: 12, 13, 14, 17, 18, 20, 21, 22, 23, 24, 26, 27, 29, 30, 31, 33, 34, 35, 37, 41, 53, 57, 58, 61, 92, 94, 97, 101, 102, 103, 104, 105, 106, 107, 108, 124, 126, 133, 135, 137, 138, 139, 140, 141, 142, 144, 145, 147, 149, 150, 152, 153, 154, 155, 156, 156/294, 159, 160, 161, 162, 163, 7/135, 12, 13, 14, 15, 16, 17/131, 18, 20, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 35, 44, 45, 46, 57, 65, 77, 85, 89, 93, 94, 97, 101, 102, 103, 105, 106, 108, 109, 110, 119, 123, 124, 126, 130, 131, 132, 133, 134, 135, 137, 138, 139, 149, 150, 153, and 156, and/or any combinations thereof. 7 . The engineered terminal deoxynucleotidyl transferase of claim 1 , wherein the polypeptide sequence comprises at least one substitution or substitution set comprising substitutions as compared to the reference sequence of SEQ ID NO: 268 at amino acid positions selected from: 14/53/300, 14/53/419, 106/300/415/419/456, 140, and 300/395/419, and/or any combinations thereof. 8 . The engineered terminal deoxynucleotidyl transferase of claim 1 , wherein the polypeptide sequence comprises at least one substitution or substitution set comprising substitutions as compared to the reference sequence of SEQ ID NO: 648 at amino acid positions selected from: 12/14/34, 12/14/34/37/94/140/141/145, 12/14/34/37/106/140/142/150/152/153, 12/14/34/37/141/142, 12/14/34/37/142/145, 12/14/34/37/142/161, 12/14/34/37/150, 12/14/34/37/150/153, 12/14/34/140/142, 12/14/34/140/150, 12/14/34/142/150/153, 12/14/92/94, 12/14/94/150/152, 12/14/106/107/141/142, 12/14/106/108/140/141/145/150, 12/14/106/108/152, 12/14/141/142, 12/14/150/152/153, 12/14/153, 12/34/92/140, 12/34/150/152, 12/37/94/141/150/152/153, 12/37/140/141/150/162, 12/161, 14, 14/31/34/37/140/141/145/161/162, 14/34/37, 14/34/37/145, 14/34/37/152, 14/34/94/106/108/141, 14/34/150/153, 14/106, 14/140, 14/141/161, 14/142, 14/142/161/162, 14/153, 14/161, 20/21/24/33/58/104/106/124/155/156, 20/21/33/58/101/104/106/124/155, 20/21/58/104/106/155/156, 20/33/104/106/124/156, 20/58/101/1
Assignees
Inventors
Classifications
DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal deoxynucleotidyl transferase · CPC title
Polynucleotides, e.g. nucleic acids, oligoribonucleotides · CPC title
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title
- C12N9/1264Primary
DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2024182876A1 cover?
- The present invention provides engineered terminal deoxynucleotidyl transferase (TdT) polypeptides useful in template-independent polynucleotide synthesis, as well as compositions, methods of utilizing these engineered polypeptides, and polynucleotides encoding the engineered terminal deoxynucleotidyl transferases.
- Who is the assignee on this patent?
- Codexis Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N9/1264. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Jun 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).